18.12.2015
- US biopharmaceutical group Amgen is buying back from GlaxoSmithKline (GSK) all of its remaining rights to the bone drugs Prolia (denosumab), Xgeva (denosumab) and Vectibix...
07.02.2013
- Amgen said it expects generic versions of biotech drugs, known as biosimilars, to be a multibillion-dollar opportunity for the company and has targeted some of the industry's...
09.01.2013
- Amgen, the world's largest biotechnology company, on Tuesday lowered its outlook for 2012 earnings per share by 10 cents, citing a delay in the impact of a U.S. tax credit for...
